Efficacy Study of Omalizumab in Cholinergic Urticaria

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

June 30, 2017

Conditions
Cholinergic Urticaria
Interventions
BIOLOGICAL

Active

Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks

BIOLOGICAL

Placebo

Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks

BIOLOGICAL

Open labeled

Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks

Trial Locations (1)

31008

Departamento de Alergología. Clínica Universidad de Navarra, Pamplona

All Listed Sponsors
collaborator

Hospital Clinic of Barcelona

OTHER

collaborator

Hospital Universitari Joan XXIII de Tarragona.

OTHER

collaborator

Hospital General Universitario Gregorio Marañon

OTHER

collaborator

Complejo Hospitalario de Navarra

OTHER

collaborator

Hospital Universitario Central de Asturias

OTHER

collaborator

Hospital Clínico Universitario Lozano Blesa

OTHER

collaborator

Hospital Vall d'Hebron

OTHER

lead

Clinica Universidad de Navarra, Universidad de Navarra

OTHER

NCT02012387 - Efficacy Study of Omalizumab in Cholinergic Urticaria | Biotech Hunter | Biotech Hunter